Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
OwnerAbd. Al-Roof Higaziinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.
Claims10
A composition including an effective amount of the polypeptide EEIIMD in the range of 2 μM to 10 μM, and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity.
(canceled)
(canceled)
(canceled)
(canceled)
A method of enhancing the fibrinolytic activity of a fibrinolytic agent, said method comprising administering in vitro an effective amount of the polypeptide EEIIMD in the range of 2 uM to 10 uM, to enhance the activity and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity.
(canceled)
(canceled)
Dependencies are inferred from the claim text.